Vemurafenib Api,Vemurafenib Cas 1029872-54-5,Vemurafenib Api Cas 1029872-54-5 Manufacturers and Suppliers in China

China Vemurafenib API Suppliers

Vemurafenib is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.

Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.

China Vemurafenib API,Vemurafenib Cas 1029872-54-5 manufacturers, welcome Vemurafenib Api Cas 1029872-54-5,Vemurafenib Indications purchasers from worldwide to visit our site.

Vemurafenib API

Top Quality Best Price Cas 1029872-54-5

Pharmaceutical Raw Material Cas 1029872-54-5

Vemurafenib API Cas 1029872-54-5

Top Quality Best Price Cas 1029872-54-5

Pharmaceutical Raw Material Cas 1029872-54-5

Vemurafenib API Cas 1029872-54-5

China Vemurafenib API Suppliers